BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Cordis Corporation (JNJ) Acquires LuMend


10/19/2005 5:12:58 PM

WARREN, N.J., Sept. 28 /PRNewswire/ -- Cordis Corporation, a Johnson & Johnson company, today announced the acquisition of LuMend, Inc., a privately held company focused on the development of chronic total occlusion (CTO) devices to treat peripheral vascular disease.

A CTO is a complete or partial blockage of an artery that can lead to surgery or lower extremity amputation. Symptoms of an occlusion in the lower limbs, the most common location, are similar to other types of vessel blockages, and may include leg pain, limping, inability to walk and sores and infections that won't heal. Treatments for CTOs range from medication to bypass surgery to less-invasive therapies. Approximately 9 million people in the U.S. have peripheral vascular disease. Only 725,000 people are diagnosed annually and less than half receive either surgical or endovascular treatment.

LuMend currently markets FRONTRUNNER(R) XP CTO and OUTBACK(R) LTD Re-Entry Catheter. Both devices facilitate the placement of a guidewire in minimally invasive procedures such as angioplasty and stenting and will complement the Cordis Endovascular portfolio of products. Cordis Endovascular is a division of Cordis Corporation.

"The combination of these businesses will enable us to bring innovative new therapies to patients and their physicians in this very important therapeutic area. We will begin this exciting new partnership by investing in the manufacturing resources and capabilities required to expand our position as a leader in delivering innovative solutions to peripheral vascular disease," said Carol Zilm, President, Cordis Endovascular.

"The acquisition of LuMend by Cordis will provide a solid foundation for sustained product development and growth in the treatment of CTOs," said Phil Hopper, CEO, LuMend, Inc.

LuMend, Inc. was founded in 1996, and today develops a full range of advanced product platforms that target chronic total occlusions in the rapidly growing peripheral vascular market. The company is focused on delivering technology and services to interventional cardiologists, radiologists and vascular surgeons specializing in endovascular techniques for the treatment of peripheral vascular disease. LuMend is based in Redwood City, CA.

Cordis Corporation, a Johnson & Johnson company, is a worldwide leader in developing and manufacturing interventional vascular technology. Through the company's innovation, research and development, physicians worldwide are better able to treat the millions of patients who suffer from vascular disease.

Cordis Endovascular, a division of Cordis Corporation, is a market leader in endovascular diagnostic catheters and a recognized leader in endovascular education, research and development. The company has the resources to develop and launch breakthrough treatments and a history of delivering reliable, quality products to customers and patients.

For more information about Cordis Corporation, visit http://www.Cordis.com

Cordis Corporation

CONTACT: Media Contact - Carol Goodrich of Cordis Corporation,+1-908-412-7332 (office), +1-973-615-4057 (mobile), or Investor RelationsContacts - Helen E. Short, +1-732-524-6491, or Stan Panasewicz,+1-732-524-2524, both of Johnson & Johnson



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES